Schrödinger is trading near 52-week lows, prompting a fresh analysis. Learn more about SDGR stock and the complexities of its ...

Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.

Gilead Sciences GILD underwent analysis by 11 analysts ... along with a high estimate of $95.00 and a low estimate of $70.00. This current average has increased by 2.65% from the previous average ...

International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely ...

Oct 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in ...

American biopharmaceutical company Gilead Sciences, on Thursday, October 3, announced that it will donate about 5,000 vials of its antiviral drug Remdesivir for emergency use in response to the ...

IAS – the International AIDS Society has lauded moves by Gilead Sciences to make generic injectable lenacapavir for HIV prevention widely available, but cautions that the current agreements still ...

(Image Credits: Pixabay) Dr. Reddy’s Laboratories Ltd. on Wednesday announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC ...

Six drugmakers have inked voluntary licensing (VL) agreements with Gilead Sciences to manufacture and distribute generic lenacapavir, a long-acting injectable HIV drug from the American drugmaker.

Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of the California-based Gilead Sciences, to manufacture and ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomed US-based Gilead Science's announcement of voluntary licensing ... it requested the company to remove the current limitation in the ...

We recognize that Gilead has included treatment use in the license, where some companies have not, but we urge that they remove the current limitation in the license to "heavily treatment-experienced ...